Related Experiment Video
Updated: Jan 16, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
CLDN4 regulates cell proliferation in small cell lung cancer cells via SAA1 inhibition
Korehito Kashiwagi1, Hanako Sato-Yazawa1, Jun Ishii1
1Department of Pathology, Dokkyo Medical University School of Medicine and Graduate School of Medicine, 880 Kita-kobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan.
Abstract:
Small cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid progression and high recurrence rates, making it a refractory cancer. However, its treatment still relies on a combination of platinum-based chemotherapy and etoposide, and a new effective therapeutic strategy is urgently needed. Claudin-4 (CLDN4) is a tight junction protein that has been reported to regulate malignant phenotypes in various types of cancer. However, its role in SCLC remains unclear. Therefore, we established CLDN4 knockout H1688 SCLC cells to evaluate its effect on malignant phenotypes, including proliferation, migration, and invasion. The results showed that CLDN4 knockout significantly promoted cell proliferation by accelerating cell cycle progression; however, it did not affect cell migration or invasion under in vitro conditions. Additionally, RNA-seq analysis identified serum amyloid A1 (SAA1) as a key downstream effector upregulated by CLDN4 knockout. SAA1 partly mediated the proliferation-promoting effect. The regulatory mechanism of CLDN4 in SCLC was also investigated. CLDN4 expression was directly regulated by SP1, with DNA methylation also contributing to its transcriptional regulation. These findings indicate that CLDN4, which is transcriptionally regulated by SP1 and DNA methylation, suppresses SCLC cell proliferation by inhibiting SAA1 expression and may serve as a potential therapeutic target.
Insights
Claudin-4 (CLDN4) suppresses small cell lung cancer (SCLC) proliferation by inhibiting serum amyloid A1 (SAA1). CLDN4, regulated by SP1 and DNA methylation, presents a potential therapeutic target for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options.
- Current SCLC treatment relies on platinum-etoposide chemotherapy, highlighting the need for novel strategies.
- Claudin-4 (CLDN4), a tight junction protein, influences cancer phenotypes, but its role in SCLC is unknown.
Purpose of the Study:
- To investigate the role of Claudin-4 (CLDN4) in small cell lung cancer (SCLC) phenotypes.
- To elucidate the downstream effectors and regulatory mechanisms of CLDN4 in SCLC.
Main Methods:
- Established CLDN4 knockout H1688 SCLC cells for phenotypic evaluation.
- Assessed proliferation, migration, and invasion in vitro.
- Utilized RNA-sequencing (RNA-seq) to identify downstream targets.
- Investigated transcriptional regulation by SP1 and DNA methylation.
Main Results:
- CLDN4 knockout significantly promoted SCLC cell proliferation by accelerating cell cycle progression.
- CLDN4 knockout did not affect cell migration or invasion in vitro.
- Serum amyloid A1 (SAA1) was identified as a key downstream effector upregulated by CLDN4 knockout, partly mediating proliferation.
- CLDN4 expression is directly regulated by SP1 and influenced by DNA methylation.
Conclusions:
- CLDN4 suppresses SCLC cell proliferation, partly through inhibition of SAA1 expression.
- CLDN4 is transcriptionally regulated by SP1 and DNA methylation.
- CLDN4 represents a potential therapeutic target for SCLC.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Cells Coordinate Growth and Proliferation
Negative Regulator Molecules
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

